New Trial Finds VEGF-Inhibitor May Safely Boost Mesothelioma Chemotherapy, According to Surviving Mesothelioma


VEGF-Inhibitor in Mesothelioma Treatment

Cediranib combined with cisplatin-pemetrexed has a reasonable toxicity profile and preliminary promising efficacy.

A new clinical trial of the VEGF-inhibitor cediranib suggests that, at the right dose, the drug might safely be used to improve the effectiveness of standard chemotherapy for pleural mesothelioma. Surviving Mesothelioma has published a new article on the trial. Click here to read it now.

For the Phase I trial, doctors at several US cancer centers helped test a mesothelioma treatment combination including the oral cancer drug cediranib the the standard mesothelioma chemotherapy drugs pemetrexed…



Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *